首页> 外文OA文献 >Development of oral agent in the treatment of multiple sclerosis: How the first available oral therapy, fingolimod will change therapeutic paradigm approach

【2h】

Development of oral agent in the treatment of multiple sclerosis: How the first available oral therapy, fingolimod will change therapeutic paradigm approach

机译：口服药物在多发性硬化症治疗中的发展：芬戈莫德首个口服药物疗法如何改变治疗范例

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Gasperini Claudio; Ruggieri Serena;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach [J] . Claudio Gasperini, Serena Ruggieri Drug Design, Development and Therapy . 2012,第5期

机译：口服药物在多发性硬化症治疗中的发展：芬戈莫德将首次采用口服药物芬戈莫德如何改变治疗范例
2. Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis [J] . Jagadeswara R Earla, George J Hutton, J Douglas Thornton, Patient Preference and Adherence . 2020,第4期

机译：多发性硬化症中口腔弓形剂和可注射疾病改性剂的比较粘附轨迹
3. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. [J] . Gold R CNS drugs . 2011,第1期

机译：多发性硬化症的口服疗法：对III期开发或近期批准的药物进行审查。
4. Identification of therapeutic inhibitors for the treatment of oral cancer using herbal bio-active principles by means of computational approach [C] . P L. Sujatha, Ravi Reddy, Jaideep Mahendra, International Conference on Advances in Electrical, Electronics, Information, Communication and Bio-Informatics . 2016

机译：利用草药生物活性原理通过计算方法鉴定治疗口腔癌的治疗抑制剂
5. Cost-Effectiveness of Oral Agents in Relapsing-Remitting Multiple Sclerosis Compared to Interferon-Based Therapy in Saudi Arabia [D] . Alskaabi, May. 2017

机译：沙特阿拉伯口服药物在复发缓解型多发性硬化症中的成本效果与基于干扰素的疗法相比
6. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy fingolimod will change therapeutic paradigm approach [O] . Claudio Gasperini, Serena Ruggieri 2012

机译：口服药物在多发性硬化症治疗中的发展：首个可用的口服药物芬戈莫德将如何改变治疗范式
7. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study [O] . Marcelo Kremenchutzky, Paul O’Connor, Reinhard Hohlfeld, 2014

机译：现有治疗现状的影响及缺陷原因对Fingolimod的疗效和安全性：亚组分析对多发性硬化症（自由）研究日常口服治疗的评估评估效果

Development of oral agent in the treatment of multiple sclerosis: How the first available oral therapy, fingolimod will change therapeutic paradigm approach

著录项

引文网络

相似文献

相关主题

期刊订阅